First Participant Enrolled in Phase 3 Trial of Fasedienol for Social Anxiety Disorder

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

Related Keywords

New York State Psychiatric Institute ,New York ,United States ,Columbia University ,Shawn Singh ,Michaelr Liebowitz ,York State Psychiatric Institute ,Drug Administration ,Research Network ,Fast Track ,Subjective Units ,Distress Scale ,Liebowitz Social Anxiety Scale ,Anxiety Disorders Clinic ,Medical Research Network ,Tales From ,Anxiety Disorder ,Vistagen Therapeutics Fast Track Designation ,